Impact of Anticoagulants and Antiplatelets in Patients on Transurethral Resection of the Prostate

Withdrawn

• Conditions: Benign Prostatic Hyperplasia; Prostate Cancer

• Registration Number: NCT02822963
• Lead Sponsor: National Cheng-Kung University Hospital

Brief Summary

Benign prostatic hyperplasia(BPH) is a common disease in urology among old men. If BPH symptom cannot be controlled by drugs, then transurethral resection of the prostate (TURP), is recommended. Although the procedure is quit safe, these old men often take anticoagulants and antiplatelets to control cardiovascular diseases, which arose some concerns for their bleeding risk. The management of anticoagulation in patients undergoing surgical procedures is challenging because interrupting anticoagulation increases the risk of thrombotic events. At the same time, surgery and invasive procedures have associated bleeding risks that are increased by the anticoagulant administration. Now, the recommendation about anticoagulants and antiplatelets discontinuation had no concrete evidence, especially in TURP. Furthermore, there is no relative studies done in Taiwan population, which calls for further investigation.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-03
• Study First Submitted: 2016-05-05
• Status Verified: 2016-06
• Study First Submitted QC: 2016-06-30
• Primary Completion: 2016-07
• Study First Posted: 2016-07-06
• Study Completion: 2016-08
• Last Update Submitted: 2020-10-04
• Last Update Posted: 2020-10-06

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

• Admitted to National Cheng Kung University Hospital Urology during the study
• Older than 20 years old
• Agree to participate this study
• Receiving transurethral resection of the prostate for benign prostatic hyperplasia or prostate cancer

Exclusion Criteria

• Poor expression ability and without close care givers to answer questions

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Urine tract infection	in 10 days after surgery
Duration of hospitalization	in 1 week after surgery
Bladder clots	in 10 days after surgery
Major bleeding	In 28 days after surgery
Perioperative blood transfusion	in 1 week after surgery
Hematuria	in 10 days after surgery
Duration of catheter	in 10 days after surgery
Cardiovascular event	In 28 days after surgery

Trial Locations

Locations (1)

National Cheng Kung University Hospital; 🇨🇳 Tainan, Taiwan